WAY-100635;WAY 100635; WAY100635
WAY-100635;WAY 100635; WAY100635
WAY-100635;WAY 100635; WAY100635 性质
| 熔点 | >145oC (dec.) |
|---|---|
| 沸点 | 594.8±50.0 °C(Predicted) |
| 密度 | 1.154±0.06 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | 甲醇（微溶）、水（微溶） |
| 形态 | 固体 |
| 酸度系数(pKa) | 6.84±0.10(Predicted) |
| 颜色 | 灰白色至浅黄色 |
| 稳定性 | 吸湿性 |
WAY-100635;WAY 100635; WAY100635 用途与合成方法
|
5-HT 1A Receptor 8.87 (pIC 50 ) |
5-HT 1A Receptor 9.71 (pA2) |
The functional properties and binding affinities of WAY-100635 are evaluated in HEK 293 cells stably expressing dopamine D
2L
or D
4.4
receptors.
WAY-100635 displays 940, 370, and 16 nM binding affinities at D
2L
, D
3
, and D
4.2
receptors, respectively. Saturation analyses demonstrat that the
K
d
of [
3
H] WAY-100635 at D
4.2
receptors is 2.4 nM. WAY-100635 is potent agonist in HEK-D
4.4
cells with
EC
50
of 9.7 nM. WAY-100635 possesses high affinity for D
4.4
receptor (3.3 nM) .
WAY-100635 (1 mg/kg; subcutaneous injection; male Sprague-Dawley rats) treatment abolishes the reduction of the severity of abstinence signs induced by Rhodiola rosea administration in nicotine-dependent rat.
| Animal Model: | Male Sprague-Dawley rats (220-240 g) |
| Dosage: | 1 mg/kg |
| Administration: | Subcutaneous injection (Pharmacokinetic study) |
| Result: | Reduced total abstinence score, increased immobility time and the burying behavior was increased. |
WAY-100635;WAY 100635; WAY100635 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-10349 | WAY-100635;WAY 100635; WAY100635 | 162760-96-5 | 5 mg | 710 |
| 2026-06-05 | HY-10349 | WAY-100635;WAY 100635; WAY100635 | 162760-96-5 | 10 mM * 1 mL in DMSO | 781 |
